The Brugada syndrome has been an area of intensive investigation since its earliest description in 1992, both on a clinical and on a basic research level. In this review, we will focus on recent achievements in the molecular dissection of the disease pathophysiology and on large multicenter studies dealing with prognostic markers and the natural history of the Brugada syndrome.
Introduction
In this article we will review current knowledge on the Brugada syndrome (BrS) [1] , focusing on diagnostic and therapeutic modalities. We will examine the most recent advances relevant to clinical management of affected patients, as well as discussing recent insights into the genetic heterogeneity of the syndrome, and the underlying pathophysiological mechanisms.
Clinical presentation and diagnosis
The incidence of BrS is estimated to be in the order of five per 10 000 [2] . Since the aberrant ECG pattern can be intermittently present or concealed, it is difficult to estimate the true prevalence of the disease in the general population. Undoubtedly, for reasons that remain elusive, the disease is either more prevalent or more penetrant in eastern countries (mainly in Southeast Asia). Although the disease is inherited as an autosomal dominant trait, there is a striking male to female ratio of 8 : 1 of clinical manifestations. It remains unknown why males have a more penetrant form of the disease.
Electrocardiographic markers
Several electrocardiographic features of BrS have been described and they may contribute to diagnosis or to risk stratification as described below.
Diagnostic criteria
Consensus exists on the fact that the electrocardiographic criteria that should be met for diagnosis consist of an ST segment elevation of at least 2 mm in at least two of the three right precordial leads (V1-V3), with a 'coved morphology' associated with incomplete or complete right bundle branch block (type 1 ECG, Fig. 1) [2]. This pattern may be spontaneously evident or it may be induced by a provocative pharmacological test with intravenous application of class Ic sodium channel blockers (ajmaline 1 mg/kg; flecainide 2 mg/kg, maximum 150 mg) [2] . It is important to recognize that the sensitivity of these criteria in the identification of affected individuals is still undefined and it is certainly lower than 100% [3] . One study suggested that the response to a provocative test has a sensitivity of 77% in the subgroup of patients carrying a mutation in the SCN5A gene [4] .
Positioning of leads for ECG recording
One factor that may influence the percentage of positive diagnoses is related to the placement of the right precordial leads. Several authors have made the observation that more patients present a coved type ECG when right precordial leads are recorded with the electrodes positioned one intercostal space upwards than the standard position. Recent data [5] suggest that patients with a diagnostic ECG with the leads positioned at a higher position have a prognosis similar to that of individuals with a type 1 ECG recorded using the standard position. A major drawback for the routine use of higher intercostal recordings is the lack of prospective studies in a large number of controls that exclude false positive results in healthy controls.
ST segment elevation in inferior leads
Some case reports [6-9] have suggested that a few individuals symptomatic for ventricular tachy-arrhythmias may present a coved-type ST segment elevation in the inferior leads in the absence of electrolyte disturbances, hypothermia or myocardial ischemia. In one family, ST segment elevation in the inferior leads and in the right precordial leads was associated with a mutation in the SCN5A gene [10] . At present, it is not possible to ascertain whether patients with a coved-type ST segment elevation in the inferior leads have a variant of BrS, and if this is the case, data are not available to define their prognosis.
Late potentials
Several investigators have studied the presence of late potentials assessed by signal-averaged electrocardiography. Whereas late potentials are commonly regarded as being representative of delayed activation of the myocardium, in the case of BrS, other possibilities have been suggested: late potentials may represent the delayed second upstroke of the epicardial action potential, a local phase 2 reentry (failing to trigger transmural reentry), or an intraventricular conduction delay [11] . Late potentials occur in approximately half of clinically affected BrS patients and should be regarded as a clinical marker of the disease. In the risk stratification section the prognostic value of late potentials will be addressed.
PR interval prolongation
It is possible that BrS patients with and without an SCN5A mutation can be differentiated on conduction parameters: a PR interval of at least 210 ms and an HV interval of at least 60 ms seem to be predictive of the presence of an SCN5A mutation [12] . Accordingly, loss-of-function SCN5A mutations can lead to isolated cardiac conduction defects or Lev-Lenè gre disease [13] . The latter syndrome is characterized by disturbances in any part of the conduction system without prolongation of the QT interval or Brugada ECG signs [13] . Identification of the modifiers that will ultimately determine the final phenotype (Brugada, Lev-Lenè gre or even an overlap syndrome [14, 15] ) is one of the current challenges for researchers in the field.
Arrhythmias and syncopal events
Full-blown BrS manifests with syncope and sudden death. Typically, cardiac events occur at rest, during sleep and they may also be triggered by hyperpyrexia [16] [17] [18] [19] , large meals (even leading to the suggestion of a 'full stomach test' as a diagnostic test in the BrS [20] ), cocaine [21, 22] and excessive alcohol consumption. The Type 1 is characterized by a coved ST segment elevation displaying ST segment elevation of at least 2 mm followed by a negative T wave with little or no iso-electric separation. Type 2 has a saddleback appearance with a high takeoff ST segment elevation of at least 2 mm, followed by gradually descending ST segment elevation (remaining 1 mm above baseline) and a positive or biphasic T wave. Type 3 has either a saddleback or coved appearance with an ST segment elevation of less than 1 mm. BrS is diagnosed when a type 1 ECG, either spontaneously or evoked by class I drug challenge, is seen in at least two of the right precordial leads (V1-V3).
age of onset of clinical manifestations (syncope or cardiac arrest) is the third to fourth decade of life, although malignant forms with earlier or neonatal onset have been reported [23] [24] [25] Although the incidence of lifethreatening events in BrS patients was thought to be very high, the most recent figures suggest that the percentage of clinically affected patients with at least one cardiac arrest before age 60 is 10-15%; thus the majority of BrS cases do not manifest life-threatening events [3].
Autonomic nervous system
Evidence has been provided suggesting that the autonomic nervous system modifies the electrocardiographic phenotype in BrS: accordingly, intravenous administration of isoproterenol attenuates while acetylcholine accentuates the ECG abnormalities in affected individuals [26] . Clinically, this correlates well with the often observed reduction of the ST elevation during the exercise test in BrS patients. Also, these findings are in agreement with the fact that the majority of events occur at rest or during sleep, hence the rationale of performing Holter monitoring to assess ST segment elevation at nighttime for diagnostic purposes.
Structural abnormalities
Actual criteria for the definition of BrS recommend the exclusion of specific structural myocardial abnormalities before a conclusive diagnosis can be reached [2]. This issue, however, has been highly debated, even before BrS was described as a clinical entity [27] . In the past 2 years, new data have emerged that are a sharp departure from the current view that BrS is a pure electrical disease: structural alterations were detected with endomyocardial biopsy in 18 patients with BrS ( Fig. 2) [28] and the right ventricular outflow tract was most severely affected by intramyocardial fibrosis in the explanted heart of a patient with ST segment elevation in the right precordial leads [29] . Thus, it may be proposed that the ECG pattern of ST segment elevation in the right precordial leads should not be seen as a marker of a specific syndrome, but rather as a common electrical manifestation of structural abnormalities in the right ventricle that may have genetic, infective, or inflammatory origins. Since these recent findings, supporting the view that subtle structural changes, such as right ventricular outflow tract dilation, may point to a localized arrhythmogenic substrate in patients with BrS, systematic cardiac MRI in the evaluation of BrS patients can be advocated [30] .
Atrial fibrillation
In approximately 10-20% of patients, supraventricular arrhythmias, especially atrial fibrillation, develop [31, 32] . This observation indicates that implantable cardioverter defibrillator (ICD) devices need to be carefully programmed in order to avoid inappropriate shocks.
Genetic bases and pathophysiology
The initial identification of SCN5A mutations in BrS was published in 1998 [33] and, as of today, tens of different mutations have been reported (see http://www.fsm.it/ cardmoc). Unfortunately, SCN5A mutations account for no more than 20% of clinically diagnosed cases. Several electrophysiological abnormalities have been identified by in-vitro functional characterization of disease-causing mutations. Interestingly, however, the overall consequence of these mutations is that of producing a loss of sodium current. This reduction in sodium current has been shown to occur through the modification of several properties of the channel, including failure of the sodium channel to express, a shift in the voltage dependence of activation or inactivation, a reduction in the rate of recovery from inactivation and accelerated inactivation subsequent to channel opening [34] [35] [36] [37] [38] . This is at variance with the effect of SCN5A mutations identified in long QT syndrome subtype 3 where mutations lead to an excess of sodium inward current (gain of function).
Recently, a novel mechanism was described for an SCN5A mutation that does not directly impair sodium current but causes a loss of binding of Nav1.5 with its intracellular target chaperone ankyrin G. Consequently, mutated Nav1.5 is not properly localized at the level of intercalated discs [39] .
Interestingly, genetic variants in the SCN5A promoter region may also have a pathophysiologic role in BrS. A haplotype of six polymorphisms in the SCN5A promoter has been identified and functionally linked to a reduced expression of the sodium current [40] . Interestingly, this variant was found among patients of Asian origin (allelic frequency 0.22) and it could play a role in modulating the expression of BrS in far eastern countries [41] .
Common SCN5A polymorphisms can influence the phenotypic expression of the disease; for example, the H558R polymorphism can rescue the trafficking-deficient R282H mutation [42] . In another study [43] , a combination of two BrS mutations (R1232W and T1620), each of which can produce functional but biophysically defective sodium channels, blocked protein trafficking of the channel. This finding offers an explanation for the severity of the disease. Finally, a disease-causing mutation itself could potentially modify the evolving phenotype: an intronic SCN5A mutation, c.4810þ 3_4810þ6dupGGGT, was shown to be the cause of BrS in a Belgian family [44, 45] . Notably, these data indicated that normal transcripts could also be derived from the mutant allele. It was speculated that the phenotypical diversity of the BrS in this family may be determined by the ratio of normal/abnormal transcripts derived from the mutant allele. These interactions could, at least in part, explain why BrS has incomplete penetrance.
The reduction of net depolarizing forces forms the basis for the two leading hypotheses that have been proposed to explain the pathophysiologic mechanisms of the syndrome (Fig. 3) . The final common pathway in both hypotheses is the same: voltage gradients between the epicardium and endocardium drive the electrotonic current causing ST segment elevations and arrhythmias based on transmural phase 2 reentry. One hypothesis ascribes the voltage gradients to conduction delay in the right ventricular epicardial free wall in the region of the outflow tract leading to asynchronous activation of subendocardial and subepicardial cells which results in voltage gradients [47] . A second hypothesis attributes the voltage gradients to premature repolarization of the right ventricular epicardial action potential [46, 48] . Reduction in the sodium current allows the transient outward current to repolarize the cell membrane during phase 1 of the action potential beyond the voltage range in which L-type Ca 2þ channels are activated. Failure of L-type [46] . (b) Activation map during pacing from the atrioventricular node at a basic cycle length of 600 ms (S1) in an explanted heart of a BrS patient. Lines are 10 ms isochrones. Numbers indicate time (ms) from stimulus. The figure shows a normal rapid spread of activation of the left septal endocardium and of the left ventricle (LV). In the right ventricular (RV) outflow tract, crowding of isochrones indicates slow conduction. Reproduced with permission from [29] . LAD, left anterior descending artery.
Ca 2þ channels to activate results in loss of the action potential plateau. Subendocardial cells express the transient outward current to a lesser extent than subepicardial cells, leading to a disparity in action potential duration between these regions, and, consequently, voltage gradients. Electrophysiological and histopathological studies on a Brugada patient's explanted heart accentuate that right precordial ST-segment elevation can be explained by localized conduction changes and does not necessitate transmural gradients in action potential duration [29] . Interestingly, the authors of this study detected interstitial fibrosis in the right ventricular outflow tract endocardium as the cause of the conduction slowing [29] .
The pivotal role of L-type Ca 2þ channels in the pathogenesis of the Brugada phenotype has been underscored very recently: loss-of-function mutations in genes encoding the cardiac L-type Ca 2þ channel (CACNA1C, the a1 subunit, and CACNAB2, the b2b subunit) have been associated with a clinical entity, encompassing a Brugada phenotype together with shorter than normal QT intervals [49] . At the present time, however, data are not available to ascertain the percentage of patients with a clinical diagnosis of BrS who carry mutations in the CACNA1C and CACNAB2 genes.
Another gene called GPD1-L, encoding for the glycerol-3-phosphate-dehydrogenase 1-like protein, has been associated with BrS [50] . A mutation was reported to cosegregate with the BrS phenotype in a single large family. The function of GPD1-L is poorly known at present, but preliminary in-vitro data suggest that it controls the membrane expression of the sodium channels and that the mutation identified in the family with BrS reduces the expression of the sodium channel [50] . We have recently performed a screening of GPD1-L in a large cohort of BrS patients with negative SCN5A screening and we showed that mutations in this gene account for no more than 1% of BrS cases (S.G. Priori, C. Napolitano, M. Memmi et al., unpublished data).
Given our limited knowledge on the genetic determinants of this syndrome, the management and risk stratification of BrS patients should be performed on a clinical basis. Nonetheless, genetic testing, when successful, allows confirmation of the diagnosis in borderline cases, identification of silent carriers and assessment of the reproductive risk.
Risk stratification and therapeutic modalities
In the next section we will review the existing knowledge on risk stratification in BrS. Additionally, the impact on decision-making processes will be highlighted.
Use of implantable cardioverter defibrillator devices and risk stratification in the Brugada syndrome
The only effective treatment to abate mortality in BrS is implantation of an ICD. Cardiac arrest survivors have a class I indication for an ICD (secondary prevention) [51] . The challenge for the clinician, however, is to define which patients require the prophylactic implant of a device (primary prevention). Indeed, risk stratification is a primary issue for BrS management. Available evidence attributes the highest risk to patients with a spontaneously abnormal ECG and a history of syncope [52] ; in these patients there is evidence in support of the use of an ICD [53] .
In the past decade, several noninvasive parameters have been proposed to be used in risk stratification schemes in BrS patients. Most parameters were lacking a substantial positive predictive value that could identify candidates for ICD therapy. Recently, a prospective study in 124 BrS patients indicated that the combination of late potentials and a spontaneous change in ST segment is associated with a high risk for subsequent events [54] . This and other studies [55] [56] [57] support the hypothesis that late potentials may be used as a noninvasive risk stratification parameter in patients with BrS; however, confirmation of these preliminary data is needed in larger populations before late potentials are applied in clinical practice.
The value of programmed electrical stimulation (PES) in the identification of high-risk asymptomatic patients is less certain. In the past, conflicting evidence has emerged on the predictive role of PES [52, 58, 59] . These contradictory conclusions leave clinicians with much uncertainty on the role of PES in BrS [60, 61] Most studies, however, continue to reinforce the opinion of most groups on the lack of a role of PES in BrS. Recently, Sacher et al. [62 ] showed that 4% of 114 asymptomatic BrS patients with a type 1 ECG and with inducible ventricular arrhythmias (n ¼ 99) experienced appropriate shocks during a mean follow-up of 31 months after ICD implantation compared with a 10% rate in patients with a type 1 ECG and syncope (n ¼ 88, mean follow-up 39.5 months) and a 22% rate in patients with a type 1 ECG and resuscitated sudden cardiac death (SCD) (n ¼ 18, mean follow-up 25.5 months). The rate of appropriate shocks received was statistically different between asymptomatic/syncope patients (P ¼ 0.02) and asymptomatic/resuscitated sudden cardiac death patients (P ¼ 0.002). Of interest, 11 of 18 BrS patients implanted with ICDs after a resuscitated SCD underwent PES, and only four of these patients had an inducible ventricular arrhythmia; these data question the role of PES in risk stratification of BrS patients [62 ,63 ] .
Based on the lack of predictive value consistently observed in our patients (in our studies performed in 2000 and 2002) and on the studies from other groups that have supported the same view [59,62 ,63 ] , we feel that clinicians should make a reasoned decision on whether they wish to recommend PES as a risk-stratifying tool in BrS supported by the fact that the American College of Cardiology (ACC)/American Heart Association (AHA)/ European Society of Cardiology (ESC) guidelines for the prevention of SCD and for the treatment of ventricular arrhythmias give a class IIb recommendation to the use of PES in BrS [51] . The PRELUDE study that we are coordinating under the auspices of the Italian Electrophysiology Society AIAC will provide a prospective evaluation of the role of PES in patients with type I BrS ECG. It is expected that this study will contribute to this debate because it will provide for the first time prospective data on a population of patients studied with the same PES protocol.
Although studies so far have not demonstrated the positive predictive value of a positive familial history of SCD, it would be reasonable to implant an ICD in an asymptomatic BrS patient with a type 1 ECG who has lost a family member due to SCD and the quality of life of the patient has been severely impaired by anxiety related to the presence of the disease. It should be kept in mind, however, that the decision to implant an ICD in a young patient should be carefully weighed against the cost in terms of quality of life of the patient who will carry an ICD for several decades. It should also be highlighted that a high rate of inappropriate shocks has been reported in this patient population [53, 62 ] .
Pharmacological therapy in the Brugada syndrome
As b-blockers are supposed to be the only antiarrhythmic compounds with a SCD reduction benefit and without proarrhythmic activity, it seems reasonable to include them in therapeutic regimens for BrS. The lack of proarrhythmicity has been challenged by the fact that shortterm b-blockade could enhance ventricular arrhythmia induction in sudden unexplained death syndrome (SUDS) patients (a disease allelic to BrS) [64] and by normalization of ST segment elevation by isoproterenol [26] . In the Defibrillator Versus b-Blockers for Unexplained Death in Thailand (DEBUT) trial [65] , SUDS survivors were randomized to ICD or b-blockers. The study investigators concluded that ICD treatment was superior to b-blocker treatment [66] . At present, there is no indication to consider the use of b-blockers in BrS; in fact, due to worsening of the ST segment elevation pattern, they have also been contraindicated (see below).
Quinidine, a nonspecific blocker of the transient outward current, has been proposed as a gene-specific therapy for BrS. The available clinical data show that quinidine prevents arrhythmia inducibility on PES in up to 76% of BrS patients and suggest a positive long-term effect in preventing the occurrence of spontaneous arrhythmias [66] . Although no final proof of effectiveness is available, quinidine may be regarded as an adjunctive therapy for patients at higher risk and to reduce the number of ICD shocks in patients with multiple recurrences.
Besides this gene-specific therapy, even more tailored approaches have been proposed. Some SCN5A mutations impair protein trafficking [67] . Interestingly, mexiletine was able to restore the sodium current by rescuing the proper localization of the protein. Mexiletine, therefore, has the potential to be used as a mutation-specific therapy [68] .
General recommendations for the management of Brugada syndrome patients
Several drugs have been reported to exacerbate the ECG pattern of ST segment elevation in BrS and to trigger arrhythmias. These compounds should obviously be avoided: antiarrhythmics (class Ia, Ic, b-blockers), tricyclic antidepressants (relative contraindication for nontricyclic antidepressants), local anesthetics (bupivacaine), opioid analgesics (propoxyphene), propofol, potassium channel activators (pinacidil), lithium, cocaine, a-adrenergic agonists (methoxamine).
Furthermore, hyperpyrexia has been consistently reported as a trigger for fatal events and therefore lowering of body temperature during febrile illnesses by appropriate pharmacological means is recommended in all patients.
According to recent guidelines, sports activities should be restricted in BrS patients [69] .
Arrhythmic storm in the Brugada syndrome
Arrhythmic storm is an exceptional finding in BrS. Lowdose intravenous isoproterenol has been reported to suppress arrhythmic storms in BrS [70] [71] [72] . Additionally, oral quinidine therapy can be started if arrhythmic storms cannot be controlled [73] . In case of failure of these therapeutic options, radiofrequency-catheter ablation of the triggering ventricular ectopies can be attempted, but should be regarded as a highly specialized 'ultimate stage' treatment [74, 75] . In very rare cases, BrS patients suffering from recurrent arrhythmic storms, refractory to any other treatment, should be considered candidates for cardiac transplantation.
Conclusions
Fifteen years after the original description of BrS, several major aspects of this disease remain unanswered. We have reviewed the unresolved issues relating to diagnosis and risk stratification of patients, highlighting that the presence of a diagnostic ECG is associated with clinical symptoms in a minority of patients, thus leaving open the dilemma of how to manage asymptomatic patients. At present, there is strong agreement on the fact that the ICD is recommended in secondary prevention of cardiac arrest and in primary prevention of cardiac arrest in patients presenting a spontaneous type I ECG and history of symptoms. How to handle other groups of patients still remains under debate. The lack of accurate risk stratification parameters leaves the clinician in a difficult situation, especially because no pharmacological treatment of the disease is available. Genetic analysis is still limited by the fact that, based on current knowledge, only a small percentage of patients can be genotyped. Thus a negative result of genetic screening cannot be used to exclude the presence of the disease. Finally, data showing the occurrence of inappropriate ICD shocks in patients with prophylactic implant of a device reinforce the need to target the use of ICDs. One of the most important issues under debate in the management of BrS relates to the pediatric population, as data on the prognosis of children with a diagnostic ECG are insufficient to attempt establishing a program for their management.
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